Centene fondaparinux coverage update

Coverage Criteria

inv-01: Initial Therapy / Indications

Covered when ALL of the following are met:

Indication requirement: Requested use corresponds to listed prophylaxis or treatment indications (surgical prophylaxis including hip fracture, hip/knee replacement, abdominal surgery; cancer-associated thrombosis; ICU/critical illness; implanted vascular devices; restricted mobility with acute illness; acute DVT/PE treatment).

Indication must be documented

Enoxaparin rule: Enoxaparin is contraindicated OR there is documented failure of a trial of enoxaparin unless there is a history of clinically significant adverse effects to LMWH or heparin (eg, HIT), allergy, OR the requested use is FDA‑labeled for fondaparinux but not for enoxaparin (eg, hip fracture surgery prophylaxis; PE treatment).

Step therapy/exception logic

Generic requirement: If request is for Arixtra (brand), member must use generic fondaparinux unless contraindicated or clinically significant adverse effects to generic are experienced.

Brand restriction

inv-02: Continued Therapy

Continued therapy covered when ALL of the following are met:

Continuation eligibility: Member is currently receiving medication via Centene benefit OR member previously met initial approval criteria OR member is enrolled in a state/product with continuity of care regulations.

Continuation paths

Clinical response: Member is responding positively to therapy (documented clinical benefit).

Response requirement

Permitted indications for extended use: Continued use is limited to thrombosis/thromboembolism indications including venous thrombosis prophylaxis/treatment in the presence of cancer; past history of failed anticoagulation on warfarin; other indications where bridging to warfarin is inappropriate or there is a contraindication to warfarin requiring extended anticoagulation.

Allowed continuation indications

inv-03: Anticoagulation in Pregnancy (Ante- and Postpartum)

Anticoagulation in Pregnancy (off-label) covered when ALL of the following are met:

Pregnancy indications: Member is pregnant or within 6 months postpartum AND has one of the following: acute venous thrombosis during current pregnancy; prior venous thrombosis; prosthetic heart valve; receiving long‑term therapy with a vitamin K antagonist (eg, warfarin); inherited thrombophilia; antiphospholipid antibody syndrome; development of severe ovarian hyperstimulation syndrome post assisted reproduction; or cesarean section in current pregnancy with request for the postpartum period.

Enumerated pregnancy-related indications

LMWH contraindication in pregnancy: History of clinically significant adverse effects or allergy to LMWH or heparin (eg, HIT) must be present to justify use of fondaparinux in pregnancy.

Justifies off-label fondaparinux in pregnancy

Generic requirement pregnancy: If request is for Arixtra (brand), member must use generic fondaparinux unless contraindicated or clinically significant adverse effects to generic are experienced.

Brand restriction for pregnancy use

inv-04: General coverage criteria

Covered when ALL of the following are met for the relevant indication

General requirements: Indication corresponds to approved uses (VTE prophylaxis in specified surgical/medical patients, treatment of acute DVT/PE, unstable angina/non‑Q wave MI, cancer‑associated VTE, and pediatric VTE where applicable); dosing and duration are consistent with policy dosing tables; and no contraindications are present.

See contraindications and dosing specifics in other nodes

inv-05: DVT prophylaxis

Covered prophylaxis dosing (examples provided in policy)

Prophylaxis dosing: Examples: 2.5 mg SC once daily for DVT prophylaxis following hip fracture, hip/knee replacement and abdominal surgery. Policy also cites alternative prophylaxis regimens in some sections (eg, 30 mg SC every 12 hours or 40 mg SC once daily for certain replacement surgery/medical patients); apply the dosing table appropriate to the member's indication.

Policy lists multiple dosing regimens across sections; verify appropriate regimen for indication

inv-06: Acute DVT/PE treatment

Covered treatment dosing (examples provided in policy)

Treatment dosing: Weight‑based treatment dosing examples: inpatient/outpatient regimens include 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily; alternate fixed dosing by weight bands also cited as 5 mg (<=50 kg), 7.5 mg (50–100 kg), or 10 mg (>=100 kg) SC once daily depending on reference in policy.

Follow weight‑based dosing per prescribing information

Non‑FDA approved indications that are not specifically addressed by this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with Centene off‑label use policies (see CP.CPA.09 for Commercial and HIM.PA.154 for Health Insurance Marketplace).

Use of fondaparinux is excluded when contraindications are present. Contraindications include: active major bleeding, bacterial endocarditis, thrombocytopenia associated with a positive in vitro anti‑platelet antibody test in the presence of fondaparinux, and a history of serious hypersensitivity to Arixtra (e.g., angioedema or anaphylactoid/anaphylactic reactions). The policy also highlights the boxed warning for risk of spinal/epidural hematomas.

Requests for fondaparinux for non‑FDA approved indications that lack sufficient supporting documentation as required by the off‑label use policies may be considered not medically necessary. Providers should follow CP.CPA.09 (Commercial) or HIM/Medicaid off‑label procedures when submitting clinical rationale and evidence.

Fondaparinux is considered not medically necessary for VTE prophylaxis in patients with body weight 50 kg. Requests for prophylactic use in this weight group should be denied per policy.

Initial Therapy

inv-25: Initial Therapy

Initial approval requires documented indication plus enoxaparin contraindication or trial/failure unless specific exceptions apply.

Indication requirement: Requested use corresponds to listed prophylaxis or treatment indications (surgical prophylaxis, cancer‑associated thrombosis, ICU/critical illness, implanted devices, restricted mobility, acute DVT/PE, pediatric VTE).

Indication must be documented

Enoxaparin consideration: Enoxaparin is contraindicated OR there is documented failure of enoxaparin unless history of clinically significant adverse effects to LMWH/heparin (eg, HIT) OR the requested use is FDA‑labeled for fondaparinux but not enoxaparin.

Step therapy/exception logic

Generic requirement initial: If request is for Arixtra (brand), member must use generic fondaparinux unless contraindicated or clinically significant adverse effects to generic are experienced.

Continuation Therapy

inv-27: Continuation Therapy

Continuation requirements mirror initial criteria and require evidence of prior approval or current therapy and clinical benefit.

Continuation eligibility: Member currently receiving medication via Centene benefit OR previously met initial approval criteria OR enrolled in a state/product with continuity of care regulations.

Continuation eligibility

Ongoing indication and benefit: Member continues on therapy if initial criteria were met and ongoing clinical indication persists with documented clinical benefit (response).

Continuation requires evidence of benefit

Permitted continuation indications: Continued use limited to thrombosis/thromboembolism indications including VTE prophylaxis/treatment in cancer, history of failed anticoagulation on warfarin, or where bridging to warfarin is inappropriate or contraindicated.

Allowed continuation indications

Step Therapy and Sequencing

Step	Requirement	Exceptions
1	Trial and failure of enoxaparin is required prior to approval of fondaparinux.	No trial required if enoxaparin is contraindicated; history of clinically significant adverse effects to LMWH or heparin (e.g., HIT) or allergy; or the requested use is FDA‑labeled for fondaparinux but not enoxaparin (e.g., hip fracture surgery prophylaxis; PE treatment).

Context	Policy guidance	Clinical examples
Therapy sequencing and alternative anticoagulants	Selection and sequencing of anticoagulants should follow NCCN and other guideline recommendations; fondaparinux may be used as an option when heparin products (heparin or LMWH) are unsuitable or contraindicated.	Examples include use of fondaparinux as monotherapy per NCCN for cancer‑associated VTE and transition to fondaparinux for patients with heparin‑induced thrombocytopenia after stabilization on a direct thrombin inhibitor (when no contraindications or invasive procedures are planned).

Coding and Dosing

HCPCS Codes referencedHCPCS

J1652

Injection, fondaparinux sodium; 0.5 mg

Weight-based dosing thresholds — Treatment dosing examples

Treatment dosing by weight<=50 kg: 5 mg SC daily; 50–100 kg: 7.5 mg SC daily; >=100 kg: 10 mg SC daily (weight-based treatment examples from policy)

Maximum daily doseMaximum example dose for treatment listed as 10 mg per day

Pediatric noteSeparate pediatric VTE dosing provided elsewhere (policy addresses pediatric VTE ≥1 year and ≥10 kg); follow pediatric-specific tables

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for fondaparinux (Arixtra) claims. Requests must include documentation that the member meets the listed medical necessity criteria for the requested indication.

Affected drugs: fondaparinux (generic) and Arixtra (brand)
Prior authorization required before service or dispensing

Documentation Required

Documentation Submission Required

Provider must submit documentation (e.g., office chart notes, laboratory results, imaging, operative reports, or other clinical information) supporting that the member has met all applicable approval criteria. Lack of sufficient documentation to demonstrate criteria are met may result in denial.

Include documentation of diagnosis, prior therapies, contraindications, and relevant labs (e.g., platelet testing when HIT suspected)
Clinical rationale required for off-label uses per applicable off‑label policies

Background

Fondaparinux (Arixtra) is a synthetic pentasaccharide factor Xa inhibitor used as an anticoagulant. It is FDA‑indicated for prophylaxis of deep vein thrombosis (DVT) in specified surgical settings (hip fracture surgery, hip or knee replacement, abdominal surgery at risk for thromboembolic complications) and for the treatment of acute DVT and acute pulmonary embolism (PE) when administered with warfarin. Product availability includes single‑dose prefilled syringes in 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths; the policy also addresses dosing and use in pediatric patients (VTE treatment in children ≥1 year and ≥10 kg) and notes safety considerations such as hypersensitivity reactions and the boxed warning for spinal/epidural hematomas.

Definitions

LMWH (therapeutic alternatives and trial/failure role)

DefinitionLow molecular weight heparin (LMWH) — e.g., enoxaparin, dalteparin — listed as therapeutic alternatives in Appendix B and referenced in step-therapy requirements

Role in policyTrial and failure of enoxaparin (an LMWH) is required prior to fondaparinux unless enoxaparin is contraindicated or exceptions apply

Formulary noteLMWH agents may require authorization and may not be formulary for all lines of business

HIT (heparin‑induced thrombocytopenia) — justification for fondaparinux use

DefinitionHeparin-induced thrombocytopenia (HIT) — cited as a history that may justify fondaparinux use when LMWH/heparin are contraindicated

Therapy sequencingPolicy describes transition to fondaparinux for patients with HIT after stabilization on a direct thrombin inhibitor

Quantity Limits

Fondaparinux product availability — prefilled syringe strengths

Available prefilled syringe strengths2.5 mg

Available prefilled syringe strengths5 mg

Available prefilled syringe strengths7.5 mg

Available prefilled syringe strengths10 mg

Site of Care

Note

Policy applies to hospital inpatient and outpatient transitions

The policy applies to both inpatient and outpatient hospital settings for prophylaxis and treatment; it specifically describes transitions from inpatient direct thrombin inhibitors to fondaparinux for stabilized HIT patients.

OpenPayer

Clinical Policy: Fondaparinux (Arixtra) - Coverage Criteria